Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6C1R

Crystal structure of human C5a receptor in complex with an orthosteric antagonist PMX53 and an allosteric antagonist avacopan

Summary for 6C1R
Entry DOI10.2210/pdb6c1r/pdb
Related6C1Q
Related PRD IDPRD_002303
DescriptorSoluble cytochrome b562, C5a anaphylatoxin chemotactic receptor 1 chimera, PMX53, avacopan, ... (9 entities in total)
Functional Keywordsgpcr, membrane protein-inhibitor complex, membrane protein/inhibitor
Biological sourceEscherichia coli
More
Total number of polymer chains2
Total formula weight51206.42
Authors
Liu, H.,Wang, L.,Wei, Z.,Zhang, C. (deposition date: 2018-01-05, release date: 2018-05-30, Last modification date: 2023-11-15)
Primary citationLiu, H.,Kim, H.R.,Deepak, R.N.V.K.,Wang, L.,Chung, K.Y.,Fan, H.,Wei, Z.,Zhang, C.
Orthosteric and allosteric action of the C5a receptor antagonists.
Nat. Struct. Mol. Biol., 25:472-481, 2018
Cited by
PubMed Abstract: The C5a receptor (C5aR) is a G-protein-coupled receptor (GPCR) that can induce strong inflammatory response to the anaphylatoxin C5a. Targeting C5aR has emerged as a novel anti-inflammatory therapeutic method. However, developing potent C5aR antagonists as drugs has proven difficult. Here, we report two crystal structures of human C5aR in ternary complexes with the peptide antagonist PMX53 and a non-peptide antagonist, either avacopan or NDT9513727. The structures, together with other biophysical, computational docking and cell-based signaling data, reveal the orthosteric action of PMX53 and its effect of stabilizing the C5aR structure, as well as the allosteric action of chemically diverse non-peptide C5aR antagonists with different binding poses. Structural comparison analysis suggests the presence of similar allosteric sites in other GPCRs. We also discuss critical structural features of C5aR in activation, including a novel conformation of helix 8. On the basis of our results, we suggest novel strategies for developing C5aR-targeting drugs.
PubMed: 29867214
DOI: 10.1038/s41594-018-0067-z
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.2 Å)
Structure validation

227344

PDB entries from 2024-11-13

PDB statisticsPDBj update infoContact PDBjnumon